Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):374-81

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  LATEST ADVANCES IN RADIOPHARMACOLOGY AND RADIOPHARMACY 2009


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):374-81

lingua: Inglese

The use of imaging in preclinical drug development

Vanderheyden J. L.

GE Healthcare, Healthcare Systems, Molecular Imaging, Waukesha, WI, USA


FULL TEXT  


Molecular imaging tools, both equipment and agents, continue to improve and evolve, offering multimodality imaging with greater sensitivity and high-resolution of biological processes in real time. This review summarizes some of these recent developments in preclinical hardware, wetware and software, and their impact on drug development. The focus is on the advances in non-invasive small animal imaging such as positron emission tomography (PET), computed tomography (CT) and solid state detectors in single photon emission tomography (SPECT), which, when combined with labeled tracers serving as biomarkers and functional probes in vivo, are demonstrating the potential to accelerate our understanding of disease and help select drug candidates for development.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

jeanluc.vanderheyden@ge.com